Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$2.12 -1.4%	$1.55	$1.11 ▼ $5.00	$564.22M	1.76	1.56 million shs	1.89 million shs
JNCE Jounce Therapeutics	$1.88	$1.89	$0.58 ▼ $5.87	$98.94M	0.75	2.46 million shs	169,314 shs
TECX Tectonic Therapeutic	$21.89 -2.5%	$20.58	$13.70 ▼ $61.07	$408.75M	3.25	173,408 shs	155,942 shs
TRML Tourmaline Bio	$19.68 -1.1%	$16.23	$11.56 ▼ $29.79	$505.48M	2.05	275,218 shs	154,595 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	0.00%	-9.40%	+64.34%	+13.37%	-51.15%
JNCE Jounce Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
TECX Tectonic Therapeutic	0.00%	-5.07%	+5.80%	-14.59%	+2,188,999,900.00%
TRML Tourmaline Bio	0.00%	+2.13%	+26.80%	+4.68%	+21.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUTL Autolus Therapeutics	2.5609 of 5 stars	3.5	1.0	0.0	0.0	2.6	3.3	0.6
JNCE Jounce Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	3.287 of 5 stars	3.6	2.0	0.0	0.0	2.1	5.0	0.6
TRML Tourmaline Bio	2.8478 of 5 stars	3.5	3.0	0.0	0.0	3.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	3.00	Buy	$9.32	339.62% Upside
JNCE Jounce Therapeutics	0.00	N/A	N/A	N/A
TECX Tectonic Therapeutic	3.25	Buy	$82.33	276.12% Upside
TRML Tourmaline Bio	3.00	Buy	$49.33	150.68% Upside

Current Analyst Ratings Breakdown

Latest JNCE, TRML, TECX, and AUTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/11/2025	TECX Tectonic Therapeutic	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$76.00
6/6/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$87.00
6/5/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/15/2025	TECX Tectonic Therapeutic	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$51.00 ➝ $85.00
5/5/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
5/5/2025	TRML Tourmaline Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
4/23/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$70.00
4/21/2025	TECX Tectonic Therapeutic	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$51.00
4/10/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/1/2025	AUTL Autolus Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$9.01M	62.61	N/A	N/A	$0.64 per share	3.31
JNCE Jounce Therapeutics	$82M	1.21	N/A	N/A	$3.54 per share	0.53
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	$2.13 per share	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	$10.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$208.38M	-$0.88	N/A	N/A	N/A	N/A	-63.65%	-36.54%	8/14/2025 (Estimated)
JNCE Jounce Therapeutics	-$50.92M	-$2.56	N/A	N/A	N/A	N/A	-30.90%	-26.31%	N/A
TECX Tectonic Therapeutic	$12.16M	-$7.31	N/A	N/A	N/A	N/A	-35.53%	-31.97%	8/13/2025 (Estimated)
TRML Tourmaline Bio	-$42.12M	-$3.21	N/A	N/A	N/A	N/A	-20.97%	-20.56%	8/6/2025 (Estimated)

Latest JNCE, TRML, TECX, and AUTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million
5/8/2025	Q1 2025	TECX Tectonic Therapeutic	-$1.10	-$0.93	+$0.17	-$0.93	N/A	N/A
5/2/2025	Q1 2025	TRML Tourmaline Bio	-$0.91	-$0.89	+$0.02	-$0.89	N/A	N/A
3/20/2025	Q4 2024	AUTL Autolus Therapeutics	-$0.21	-$0.09	+$0.12	-$0.09	$2.98 million	$0.03 million
3/20/2025	Q4 2024	TECX Tectonic Therapeutic	-$1.39	-$0.84	+$0.55	-$0.84	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
JNCE Jounce Therapeutics	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	13.69	13.69
JNCE Jounce Therapeutics	N/A	8.37	8.37
TECX Tectonic Therapeutic	N/A	9.39	9.39
TRML Tourmaline Bio	N/A	40.33	40.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
JNCE Jounce Therapeutics	80.66%
TECX Tectonic Therapeutic	62.63%
TRML Tourmaline Bio	91.89%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
JNCE Jounce Therapeutics	6.92%
TECX Tectonic Therapeutic	38.00%
TRML Tourmaline Bio	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.71 million	Optionable
JNCE Jounce Therapeutics	137	52.63 million	48.99 million	Optionable
TECX Tectonic Therapeutic	120	18.67 million	13.40 million	N/A
TRML Tourmaline Bio	44	25.69 million	22.82 million	Optionable

JNCE, TRML, TECX, and AUTL Headlines

Recent News About These Companies

Cantor Fitzgerald Weighs in on Tourmaline Bio FY2026 Earnings

June 11, 2025 | marketbeat.com

Two Sigma Investments LP Sells 21,904 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)

June 10, 2025 | marketbeat.com

Tourmaline Bio Elects Directors and Ratifies Auditor

June 6, 2025 | tipranks.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Bought by Bank of America Corp DE

June 6, 2025 | marketbeat.com

Tourmaline Bio (NASDAQ:TRML) Trading Up 7.2% - Here's What Happened

June 5, 2025 | marketbeat.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of "Buy" from Brokerages

May 31, 2025 | marketbeat.com

H.C. Wainwright maintains $50 target on Tourmaline Bio stock

May 29, 2025 | uk.investing.com

H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results

May 29, 2025 | msn.com

Millennium Management LLC Has $7.40 Million Position in Tourmaline Bio, Inc. (NASDAQ:TRML)

May 28, 2025 | marketbeat.com

Leerink Partnrs Comments on Tourmaline Bio FY2026 Earnings

May 27, 2025 | marketbeat.com

29,844 Shares in Tourmaline Bio, Inc. (NASDAQ:TRML) Purchased by Rafferty Asset Management LLC

May 25, 2025 | marketbeat.com

BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML)

May 23, 2025 | msn.com

Wexford Capital LP Purchases New Position in Tourmaline Bio, Inc. (NASDAQ:TRML)

May 22, 2025 | marketbeat.com

Tourmaline shares waver as investors mull mid-stage pacibekitug data

May 21, 2025 | thepharmaletter.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Stake Increased by Velan Capital Investment Management LP

May 21, 2025 | marketbeat.com

Tourmaline touts cardiovascular potential of former Pfizer antibody after phase 2 kidney disease win

May 21, 2025 | fiercebiotech.com

Tourmaline Bio posts mid-stage data for anti-inflammatory agent

May 21, 2025 | msn.com

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition

May 20, 2025 | seekingalpha.com

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

May 19, 2025 | globenewswire.com

Tourmaline Bio Reports Q1 2025 Financial Results

May 7, 2025 | tipranks.com

Why Tourmaline Bio, Inc.’s (TRML) Stock Is Down 7.00%

May 3, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JNCE, TRML, TECX, and AUTL Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$2.12 -0.03 (-1.40%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.12 +0.00 (+0.24%)

As of 06/13/2025 07:46 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Jounce Therapeutics NASDAQ:JNCE

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Tectonic Therapeutic NASDAQ:TECX

$21.89 -0.55 (-2.45%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$21.89 0.00 (0.00%)

As of 06/13/2025 04:44 PM Eastern

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

Tourmaline Bio NASDAQ:TRML

$19.68 -0.22 (-1.11%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$19.68 +0.00 (+0.03%)

As of 06/13/2025 04:25 PM Eastern

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time